Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rapid Micro Biosystems (RPID) EBT Margin (2020 - 2025)

Rapid Micro Biosystems' EBT Margin history spans 6 years, with the latest figure at 146.68% for Q3 2025.

  • For Q3 2025, EBT Margin rose 205.0% year-over-year to 146.68%; the TTM value through Sep 2025 reached 145.05%, up 3972.0%, while the annual FY2024 figure was 167.08%, 6577.0% up from the prior year.
  • EBT Margin for Q3 2025 was 146.68% at Rapid Micro Biosystems, up from 163.14% in the prior quarter.
  • Across five years, EBT Margin topped out at 117.73% in Q4 2024 and bottomed at 442.08% in Q1 2021.
  • The 5-year median for EBT Margin is 237.37% (2024), against an average of 253.67%.
  • The largest annual shift saw EBT Margin crashed -20094bps in 2021 before it skyrocketed 19969bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 279.78% in 2021, then tumbled by -34bps to 375.86% in 2022, then surged by 53bps to 176.17% in 2023, then soared by 33bps to 117.73% in 2024, then decreased by -25bps to 146.68% in 2025.
  • Per Business Quant, the three most recent readings for RPID's EBT Margin are 146.68% (Q3 2025), 163.14% (Q2 2025), and 156.22% (Q1 2025).